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A decreased expression of the fibroblast growth factor (FGF)-
23 coreceptor Klotho was postulated as an early alteration in
chronic kidney disease mineral and bone disorder, resulting
in a compensatory increase in plasma FGF-23 levels. Klotho
exists in both membrane-bound and secreted (sKlotho)
forms, the latter of which may exert vasculoprotective effects.
Here we analyzed plasma sKlotho levels in a large cohort of
312 patients with stage 2–4 chronic kidney disease, and
assessed plasma levels of FGF-23, sKlotho, parathyroid
hormone, and urinary fractional phosphate excretion.
Patients were prospectively followed for an average of
2.2 years for the occurrence of death or initiation of renal
replacement therapy. The levels of sKlotho were significantly
associated with age, but not with the glomerular filtration
rate or other parameters of calcium-phosphate metabolism.
Moreover, while patients with high FGF-23 levels faced worst
outcome even after adjustment for confounders, we found
no prognostic impact of sKlotho. Thus, plasma levels of
sKlotho were not related to kidney function and did not
predict adverse outcome in patients with chronic kidney
disease. Future studies are needed to understand how tissue
expression, urinary excretion, and plasma levels of Klotho
diverge in progressive chronic kidney disease.
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A deranged calcium-phosphate metabolism substantially
contributes to the tremendous burden of cardiovascular
morbidity and mortality in chronic kidney disease (CKD).
Starting in 1998, when Block et al.1 associated elevated
phosphate levels with high mortality in CKD patients,
numerous cohort studies identified hyperphosphatemia,
secondary hyperparathyroidism, and hypovitaminosis D as
adverse outcome predictors in CKD.2–7 Our traditional
understanding of CKD–mineral and bone disorder (CKD-
MBD) centered on the deficiency of renal 1a-hydroxylase
(CYP27B1) that accompanies the progressive loss of renal
mass. CYP27B1 physiologically converts native vitamin D
(25-OH-D3) into its active metabolite, 1,25-(OH)2-D3. Its
deficiency in CKD will therefore result in lower levels of
circulating active vitamin D, which—in conjunction with
renal phosphate retention—will cause secondary hyperpar-
athyroidism.
This traditional, vitamin D–centered understanding of
CKD-MBD was recently challenged by the identification
of the phosphaturic hormone fibroblast growth factor
(FGF)-23. Together with parathyroid hormone (PTH),
FGF-23 combats hyperphosphatemia in mild-to-moderate
CKD by inducing renal phosphate excretion. Unlike PTH,
which enhances CYP27B1 activity, FGF-23 reduces serum
levels of active vitamin D by inhibiting CYP27B1 activity and
increasing the expression of 24-hydroxylase (CYP24A1),
which controls calcitriol degradation.8 Surprisingly,
recent clinical trials identified elevated FGF-23 levels as the
earliest biological markers of a deranged calcium-phosphate
metabolism in the course of CKD.9,10 This increase in
FGF-23 levels might even precede the decline of glomerular
filtration rate at the onset of CKD.10 At present, it remains
unclear which stimuli induce FGF-23 secretion in very
early stages of CKD, in which phosphate retention has not yet
occurred.9
Of note, FGF-23 signaling requires the expression of the
transmembrane protein Klotho on target cells. Reduced levels
of plasma and urinary Klotho were reported in mice with
early CKD,11 which might require a compensatory increase in
serum levels of FGF-23. Therefore, a partial deficiency of
http://www.kidney-international.org c l in i ca l inves t iga t ion
& 2012 International Society of Nephrology
Received 9 September 2011; revised 6 June 2012; accepted 2 July 2012;
published online 15 August 2012
Correspondence: Gunnar H. Heine, Department of Internal Medicine IV -
Nephrology and Hypertension, Saarland University Hospital, Homburg/Saar,
Germany. E-mail: Gunnar.Heine@uks.eu
Kidney International (2012) 83, 121–128 121
Klotho has been postulated as the initial inducer of hyper-
FGF-23-emia in early CKD.12
Reduced Klotho expression might have an additional
pathophysiological impact: Klotho can be released from the
cell membrane into plasma. Here, secreted Klotho (sKlotho)
might exert diverse vasculoprotective functions, as reviewed
recently.12,13
The lack of an adequate serological test precluded the
analysis of sKlotho levels in earlier clinical studies. Only very
recently, enzyme-linked immunosorbent assay (ELISA)–based
quantification of sKlotho has been established, and first
human data on plasma sKlotho were reported from healthy
volunteers.14,15
Against this background, we now set out to analyze
sKlotho plasma levels in a large cohort of CKD patients.
RESULTS
The study participants’ baseline characteristics are shown in
Table 1. As expected, patients in more advanced CKD stages
were older, had higher cardiovascular comorbidity, higher
albuminuria, and higher C-reactive protein (CRP) and
plasma phosphate levels. In addition, they were more likely
to receive vitamin D supplementation. In all, 30 patients were
receiving active vitamin D analogs (alfacalcidol: 19 patients
(mean daily dose: 0.40 mg); calcitriol: 11 patients (mean daily
dose: 0.25 mg)).
Moreover, with declining renal function, patients had
significantly higher urinary fractional phosphate excretion
(FePi; P-value for trendo0.001), plasma FGF-23 (P-value for
trend o0.001), and PTH (P-value for trend o0.001) levels.
In contrast, sKlotho plasma levels did not differ across CKD
stages (P-value for trend¼ 0.098; see Figure 1a–d).
After stratifying patients for plasma sKlotho levels into
tertiles, patients in the highest sKlotho tertile were of younger
age and showed highest albuminuria, whereas patients in the
lowest sKlotho tertile were more likely to receive statin
medication. Of note, patients in the second sKlotho tertile
had the highest CRP levels. No other differences in baseline
characteristics and comorbidity were found across the three
groups (Table 2).
Among the different parameters of calcium-phosphate
metabolism, FGF-23 levels were correlated with PTH, FePi,
and phosphate levels. No association between sKlotho plasma
levels and any other parameter of calcium-phosphate
metabolism was found (Table 3).
Patients were followed up for 2.2±0.8 years (a minimum
of 0.9 years, and a maximum of 3.6 years); one patient was
lost to follow-up after 2 months. The combined end point,
defined as the occurrence of death, or as initiation of renal
replacement therapy, occurred in 29 patients (9.0%); 19
patients reached end-stage renal disease and underwent renal
replacement therapy, and 10 patients died before the onset of
Table 1 | Patients’ baseline characteristics stratified by CKD stage
Total cohort
(n=321)
CKD stage 2
(n=51)
CKD stage 3a
(n=106)
CKD stage 3b
(n=93)
CKD stage 4
(n=71) P-value
Age (years) 65.5±12.1 59.8±11.4 63.6±12.5 68.6±11.0 68.3±11.6 o0.001
Women (%) 125 (38.9) 15 (29.4) 43 (40.6) 39 (41.9) 28 (39.4) 0.489
Smokers (%) 35 (10.9) 10 (19.6) 13 (12.3) 7 (7.5) 5 (7.0) 0.116
Diabetes mellitus (%) 123 (39.4) 19 (37.3) 40 (37.7) 37 (39.8) 27 (38.0) 0.988
CVD (%) 105 (32.7) 6 (11.8) 32 (30.2) 40 (43.0) 27 (38.0) o0.001
CRP (mg/l) 2.7 (1.2–5.1) 2.4 (1.7–4.3) 2.5 (1.1–5.3) 2.7 (1.2–5.0) 3.3 (1.1–5.4) 0.046
Total cholesterol (mg/dl) 193.2±42.8 204.9±35.5 190.0±40.8 189.5±43.1 194.2±49.1 0.308
HDL-C (mg/dl) 49.8±16.4 49.9±13.8 51.0±16.8 49.2±16.3 48.6±17.8 0.437
LDL-C (mg/dl) 117.1±35.2 128.1±30.5 114.4±33.9 113.8±34.6 117.7±39.8 0.212
BMI (kg/m2) 30.4±5.5 30.8±6.2 30.7±5.5 30.9±5.7 29.2±4.4 0.118
Calcium (mmol/l) 2.4±0.1 2.3±0.1 2.4±0.1 2.4±0.1 2.3±0.2 0.574
Phosphate (mg/dl) 3.4±0.7 3.0±0.5 3.3±0.5 3.4±0.8 3.9±0.7 o0.001
FGF-23 (rU/ml) 99 (60–159) 57 (45–86) 71 (48–101) 117 (82–169) 176 (121–259) o0.001
sKlotho (pg/ml) 538 (450–666) 554 (472–757) 550 (462–665) 536 (443–661) 530 (429–678) 0.098
PTH (pg/ml) 71.1±59.1 45.9±21.9 48.5±25.4 67.6±42.4 127.4±88.3 o0.001
eGFR (ml/min per 1.73 m2) 43.8±15.6 67.6±5.8 51.8±4.1 38.2±4.4 22.2±4.2 o0.001
Albuminuria (mg/g) 37 (8–201) 28 (8–188) 18.3 (6–106) 43 (7–140) 127 (39–633) o0.001
FeCa (%) 0.7±0.8 0.5±0.4 0.6±0.5 0.8±1.0 0.8±1.0 0.824
FePi (%) 26.4±13.1 17.6±7.7 20.3±9.0 28.1±10.5 40.0±13.4 o0.001
BB (%) 217 (69.6) 25 (49.0) 72 (67.9) 73 (78.5) 47 (66.2) 0.004
ACE-I (%) 129 (40.2) 20 (39.2) 46 (43.4) 37 (39.8) 26 (36.6) 0.836
ARB (%) 158 (50.6) 27 (52.9) 55 (51.9) 46 (49.5) 30 (42.3) 0.580
Statin (%) 156 (48.6) 16 (31.4) 53 (50.0) 50 (53.8) 37 (52.1) 0.058
Native vitamin D (%) 140 (43.6) 21 (41.2) 37 (34.9) 39 (41.9) 43 (60.0) 0.007
Active vitamin D (%) 30 (9.3) 1 (2.0) 1 (0.9) 13 (14.0) 15 (21.1) o0.001
Abbreviations: ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; BB, b-blockers; BMI, body mass index; CKD, chronic kidney disease; CVD,
cardiovascular disease; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; FeCa, urinary fractional calcium excretion; FePi, urinary fractional phosphate
excretion; FGF-23, fibroblast growth factor-23; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PTH, parathyroid hormone; sKlotho,
secreted Klotho.
Variables are presented as percentage, or as mean±s.d., as appropriate. CRP, FGF-23, and sKlotho levels are presented as median (interquartile range) because of skewed
distribution.
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Figure 1 |Parameters of calcium-phosphate metabolism and renal function. (a) Levels of secreted Klotho (sKlotho), (b) fibroblast
growth factor-23 (FGF-23), (c) PTH (parathyroid hormone), (d) and urinary fractional phosphate excretion (FePi) stratified by KDOQI stage,
depicted as box plots. Indicated are medians, interquartile ranges (IQR), minimal and maximal values, outliers (defined as values between 1.5
and 3 times IQR, and represented by circles), and extreme values (defined as values more than three times IQR and represented by asterisks).
Note: arrows indicate six patients who had FGF-23 values higher than 1200 rU/ml. CKD, chronic kidney disease.
Table 2 | Patients’ baseline characteristics stratified by sKlotho plasma levels
sKlotho sKlotho sKlotho P-value
Tertile 1 (278.6–480.3 pg/ml) Tertile 2 (480.4–620.0 pg/ml) Tertile 3 (623.9–2130.0 pg/ml)
n=108 n=106 n=107
Age (years) 66.6±11.4 66.6±11.0 63.3±13.6 0.044
Women (%) 41 (38.0) 45 (42.5) 39 (36.4) 0.646
Smokers (%) 16 (14.8) 7 (6.6) 12 (11.2) 0.155
Diabetes mellitus (%) 40 (37.0) 35 (33.3) 48 (44.9) 0.195
CVD (%) 39 (36.1) 32 (30.2) 34 (31.8) 0.632
CRP (mg/l) 2.6 (1.3–5.6) 2.9 (1.7–5.9) 2.1 (1.0–4.4) 0.026
Total cholesterol (mg/dl) 190.0±39.2 191.2±39.2 198.4±49.3 0.152
HDL-C (mg/dl) 49.9±14.9 48.3±14.3 51.2±19.5 0.568
LDL-C (mg/dl) 113.2±34.4 118.3±32.5 120.0±38.5 0.159
BMI (kg/m2) 29.9±5.2 31.0±5.7 30.4±5.5 0.445
Calcium (mmol/l) 2.4±0.1 2.4±0.1 2.4±0.1 0.783
Phosphate (mg/dl) 3.5±0.9 3.3±0.6 3.4±0.7 0.165
FGF-23 (rU/ml) 103 (64–169) 93 (61–145) 103 (56–174) 0.348
sKlotho (pg/ml) 400 (355–452) 538 (506–572) 742 (665–837) o0.001
PTH (pg/ml) 66.3±55.9 70.7±60.4 76.2±61.0 0.471
Albuminuria (mg/g) 29 (7–185) 26 (5–106) 87 (19–615) 0.019
FeCa (%) 0.7±0.9 0.7±0.7 0.7±0.8 0.699
FePi (%) 25.8±13.3 25.1±12.1 28.3±13.9 0.193
BB (%) 75 (69.4) 75 (70.8) 67 (62.6) 0.394
ACE-I (%) 37 (34.3) 45 (42.5) 47 (43.9) 0.297
ARB (%) 53 (49.1) 50 (47.2) 55 (51.4) 0.826
Statin (%) 67 (62.0) 50 (47.2) 39 (36.4) o0.001
Native vitamin D (%) 44 (40.7) 46 (43.4) 50 (46.7) 0.378
Active vitamin D (%) 10 (9.3) 10 (9.4) 10 (9.3) 0.983
Abbreviations: ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker; BB, b-blocker; BMI, body mass index; CRP, C-reactive protein; CVD,
cardiovascular disease; FeCa, urinary fractional calcium excretion; FePi, urinary fractional phosphate excretion; FGF-23, fibroblast growth factor-23; HDL-C, high-density
lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PTH, parathyroid horomone; sKlotho, secreted Klotho.
Variables are presented as percentage, or as mean±s.d., as appropriate. CRP, FGF-23, albuminuria, and sKlotho levels are presented as median (interquartile range) because of
skewed distribution.
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end-stage disease. When stratifying patients by their sKlotho
plasma levels into tertiles, event-free survival did not differ
between the three groups (Figure 2). In contrast, after
stratifying patients by FGF-23 levels, patients with the highest
plasma levels of FGF-23 faced worst outcome (Figure 3).
In Cox regression analyses, levels of FGF-23, PTH, and
FePi all predicted adverse outcome in univariate analysis,
whereas sKlotho did not. After adjusting for age, estimated
glomerular filtration rate (eGFR), and albuminuria, FGF-23
remained an independent predictor of the combined end
point, whereas PTH and FePi did not (Table 4).
DISCUSSION
Our pathophysiological understanding of CKD-associated
derangements of calcium-phosphate metabolism has recently
been enhanced by the identification of the phosphaturic
hormone FGF-23 and its coreceptor Klotho. Early in the
course of CKD, a rise in FGF-23 levels occurs, which precedes
more traditional changes of calcium-phosphate metabolism
such as hyperparathyroidism and hyperphosphatemia.9
While preventing overt hyperphosphatemia until the onset
of end-stage renal disease, elevated FGF-23 levels were shown
to predict adverse renal16 and cardiovascular17 outcome in
nondialysis CKD patients by our group. An association
between serum FGF-23 levels and mortality in CKD stage 2–4
patients was very recently confirmed in the large prospective
CRIC cohort,18 which is in line with earlier findings in
incident dialysis patients.19
Table 3 | Spearman correlation coefficients of parameters of
calcium–phosphate metabolism and sKlotho plasma levels
sKlotho
(pg/ml)
Calcium
(mmol/l)
Phosphate
(mg/dl)
PTH
(pg/ml)
FeCa
(%)
FePi
(%)
Calcium
(mmol/l)
r=0.01
P=0.916
Phosphate
(mg/dl)
r=0.06 r=0.02
P=0.291 P=0.705
PTH (pg/ml) r=0.05 r=0.05 r=0.08
P=0.374 P=0.348 P=0.134
FeCa (%) r=0.03 r=0.07 r=0.06 r=0.07
P=0.564 P=0.248 P=0.276 P=0.203
FePi (%) r=0.05 r=0.02 r=0.05 r=0.52 r=0.10
P=0.392 P=0.778 P=0.384 Po0.001 P=0.093
FGF-23 (rU/ml) r=0.03 r=0.00 r=0.40 r=0.34 r=0.08 r=0.38
P=0.652 P=0.961 Po0.001 Po0.001 P=0.170 Po0.001
Abbreviations: FGF-23, fibroblast growth factor-23; FeCa, urinary fractional calcium
excretion; FePi, urinary fractional phosphate excretion; PTH, parathyroid hormone;
sKlotho, secreted Klotho.
Indicated are correlations coefficients (r) and levels of significance (p).
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Figure 2 | Secreted Klotho (sKlotho) levels and event-free
survival. Patients were stratified by their plasma sKlotho levels
(tertile 1: 278.6–480.3 pg/ml, tertile 2: 480.4–620.0 pg/ml, tertile 3:
623.9–2130.0 pg/ml). Kaplan–Meier analysis with log-rank test did
not reveal a significant difference between groups (P¼ 0.336).
1.0
FGF-23 (rU/ml)
Tertile 1
Tertile 2
Tertile 3
0.9
0.8
0.7
0.6E
ve
nt
-fr
ee
 s
ur
viv
al
0.5
0.4
0 1 2
Time (years)
3
P<0.001
Figure 3 | Fibroblast growth factor-23 (FGF-23) levels and
event-free survival. Patients were stratified by their plasma FGF-
23 levels (tertile 1: 14.8–71.2 rU/ml, tertile 2: 71.6–136.8 rU/ml,
tertile 3: 138.1–7273.9 rU/ml). Kaplan–Meier analysis with log-rank
test revealed a significant difference between groups (Po0.001).
Table 4 | Univariate and multivariate Cox regression analysis
(combined end-point initiation of renal replacement therapy
or death)
Univariate
analysis
Multivariate analysis
(adjusted for eGFR,
age, Lg albuminuria)
HR CI P-value HR CI P-value
Lg Klotho 1.46 0.14–15.95 0.752 1.59 0.12–20.83 0.726
PTH (pg/ml) 1.01 1.00–1.01 o0.001 1.00 1.00–1.01 0.490
FePi (%) 1.05 1.03–1.07 o0.001 1.01 0.98–1.04 0.443
Lg FGF-23 5.59 3.18–9.85 o0.001 2.49 1.12–5.54 0.025
Abbreviations: CI, 95% confidence interval; eGFR, estimated glomerular filtration
rate; FePi, urinary fractional phosphate excretion; FGF-23, fibroblast growth factor
23; HR, hazard ratio; P, level of significance; PTH, parathyroid hormone.
Klotho, FGF-23, and albuminuria values were log transformed (Lg) to approximate a
normal distribution.
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Although epidemiological data suggest that FGF-23 exerts
its detrimental impact independently of associated changes in
phosphate and PTH,16,18,19 the underlying pathophysiologi-
cal pathways remain unclear.
It is thought that FGF-23 requires Klotho as an obligatory
coreceptor on target cells. Of note, Klotho expression has
never been demonstrated in myocardial and vascular cells,
suggesting a Klotho-independent effect of FGF-23 on the
cardiovascular system. In line with this, in vivo data from
Faul et al.20 have recently strengthened this hypothesis by
revealing a Klotho-independent activation of the PLCg-
pathway in rodent myocardial cells with consecutive devel-
opment of left ventricular hypertrophy.
In contrast, subjects with intact renal function who are
genetically exposed to elevated FGF-23 levels do not suffer from
elevated cardiovascular morbidity.21 Against this background, it
has recently been suggested that reduced Klotho expression
might be the major culprit that explains the association
between elevated FGF-23 and adverse outcome in CKD.12
Quantification of membrane-bound Klotho on target cells
of FGF-23 would require invasive diagnostic procedures,
which is not feasible in large epidemiological studies.
Notably, membrane-bound Klotho is released into plasma
by membrane-anchored proteases, yielding sKlotho, which is
accessible for measurement in large-scale cohort studies.
Nevertheless, determination of plasma sKlotho became
practicable only very recently, with the advent of a sensitive
and specific ELISA,15 and sKlotho was suggested to serve not
only as a reflector of tissue Klotho expression, but even as a
potential therapeutic target in CKD.21
The first study that analyzed sKlotho was conducted by
Yamazaki et al.,15 who measured sKlotho plasma levels in
children (mean age 7.1±4.8 years) and healthy adults (mean
age 61.1±18.5 years), and found higher sKlotho levels in
children compared with adults. In analyses with combined
data from children and adults, sKlotho levels were correlated
with age, and plasma phosphate, FGF-23, and creatinine
levels. By visual inspection, exclusion of children from
analysis substantially weakens the association between
sKlotho and age. Similarly, the association of sKlotho with
creatinine and FGF-23 appears to be driven by the inclusion
of children, who had considerably lower creatinine and FGF-
23 levels compared with adults. Accordingly, these associa-
tions disappear after adjustment for age and other con-
founders. Moreover, a single study participant had a serum
creatinine value 41.0mg/dl, and thus serum creatinine
values rather reflect body composition and nutrition than
actual renal function in this cohort.
Subsequently, several cross-sectional studies analyzed
sKlotho levels in diverse (and mostly fairly small) cohorts
of CKD patients, which yielded contradictory data.22–24
Shimamura et al.25 reported significantly lower sKlotho levels
in CKD stage 2–5 patients compared with CKD stage 1
patients. Of note, this finding is largely based on data from
four young individuals with normal eGFR and extremely
high sKlotho levels, whereas sKlotho levels from the
remaining 288 participants are fully in line with our results.
Accordingly, elimination of those four outliers would
virtually erase the association between eGFR and sKlotho.
The idea of a decline in sKlotho levels with impaired kidney
function was further disputed by smaller studies.22,26
The first prospective cohort study on the prognostic
implications of sKlotho was the InCHIANTI study, which
recruited 804 older community-dwelling adults.14 In cross-
sectional analysis, lower sKlotho correlated weakly, albeit
significantly, with advanced age. Low sKlotho levels predicted
all-cause mortality within 6 years of follow-up, despite
adjustment for age, classical cardiovascular risk factors, and
traditional markers of calcium-phosphate metabolism.
Neither cause-specific mortality data nor information on
nonfatal cardiovascular events are available, and thus the
impact of low sKlotho on cardiovascular outcome remains
unknown. With a minimum age of 65 years, it is of little
surprise that the eGFR was below 60ml/min per 1.73m2 in
one out of three study participants. Unfortunately, no
detailed information on kidney function was available.
In our CARE FOR HOMe study, we investigated the
association between plasma sKlotho levels, renal function,
and mortality in a well-characterized CKD stage 2–4 cohort
with standardized follow-up examinations. Although we
confirm a weak association between sKlotho and age, we
surprisingly neither found lower sKlotho levels with declining
renal function nor any correlation of sKlotho with other
parameters of calcium-phosphate metabolism. These findings
are somewhat surprising, as sKlotho is considered to
originate from renal tubular cells, whose numbers decrease
with progressive CKD. Stable sKlotho levels across CKD
stages might be explained by extrarenal production of
sKlotho, or by an impaired renal clearance.
Our findings are in disagreement with animal data. Hu
et al.11 reported reduced expression of urinary and plasma
sKlotho in mice with early CKD, which was suggested to
result in a compensatory increase in FGF-23 levels. Therefore,
a partial Klotho deficiency was discussed as the initial inducer
of hyper-FGF-23-emia in early CKD.12 Of note, this
hypothesis is not generally accepted: in the CRIC study, an
early increase of FGF-23 was associated with subtle hypopho-
sphatemia in initial CKD stages.9 If partial Klotho deficiency
were the initial culprit in CKD-MBD that secondarily led to
enhanced FGF-23 secretion, a tendency toward hyperphos-
phatemia rather than hypophosphatemia in aggregate with
elevated levels of active vitamin D and hypercalcemia would
be expected at earliest CKD stages, given the physiological
role of sKlotho.9 As none of these changes were found in the
CRIC cohort, the initial increase of FGF-23 in early CKD was
considered a potential inducer, rather than consequence, of
Klotho deficiency.
Corroborating conclusions from these cross-sectional
analyses, our prospective data refute the assumption that
low sKlotho might predict loss of renal function and
mortality in patients with CKD. Instead, FGF-23 levels
turned out to be the best parameter of calcium-phosphate
Kidney International (2012) 83, 121–128 125
S Seiler et al.: Klotho plasma levels and CKD c l in i ca l inves t iga t ion
metabolism for predicting adverse outcome. It thereby
surpasses PTH and urinary FePi, which were associated with
progression of CKD and mortality only in univariate analysis.
Notably, these findings are in striking agreement with
mortality data from the large CRIC cohort.18
Admittedly, further experimental studies are needed to
discern the precise implications of different CKD stages on
FGF-23 and Klotho biology. In animal studies, overexpres-
sion of FGF-23 severely suppressed renal Klotho expression,27
whereas FGF-23 induced Klotho expression in parathyroid
glands.28 No changes in sKlotho levels were found in humans
genetically exposed to high FGF-23 levels.29
Animal studies suggest a statin-induced increase in Klotho
expression, which might prevent the development of athero-
sclerosis.30,31 To the best of our knowledge, the relationship
between Klotho expression and statin intake has never been
studied in humans. We now report an association between
statin medication and low, rather than high, sKlotho levels
in the present study. This finding should be interpreted
cautiously, as patients with lowest sKlotho levels were older,
and tended to have more CVD, pointing to confounding by
indication. Therefore, interventional trials are necessary to
clarify the impact of statin medication on sKlotho levels.
As a limitation, our study protocol precluded analyses of
membrane-bound Klotho, and we did not measure urinary
Klotho. Although plasma sKlotho was suggested as a reflector
of membrane-bound Klotho,21 we cannot exclude discor-
dance between Klotho tissue expression, Klotho urinary
excretion, and plasma sKlotho levels. Notably, Hu et al.11
reported a decrease in urinary Klotho excretion with the
advent of early kidney disease among 40 CKD patients, and
animal data suggest that Klotho deficiency might accelerate
kidney injury32,33 and soft-tissue calcification11 in murine
CKD models. Future studies will have to analyze how far
tissue expression, urinary excretion, and plasma secretion of
Klotho might diverge in human CKD.
Furthermore, aiming to recruit a less heterogeneous
patient cohort for outcome analysis, we deliberately chose
not to include CKD 5 patients in our study. As a
consequence, our data may not be transferred to dialysis
patients. We also did not measure sKlotho in healthy controls
or CKD stage 1 patients. Thus, we cannot formally exclude
the possibility of a threshold effect, with an initial reduction
in sKlotho occurring with very early kidney damage, but no
further decrease with advancing CKD.
Finally, our ongoing CARE FOR HOMe study was
initiated in 2008. Subsequently, only short-term follow-up
data are available at present. As we cannot detect any trend
for adverse outcome in subjects with low sKlotho in the
current analysis, we are nevertheless skeptical that longer
follow-up would yield a significant and clinically meaningful
difference in outcome.
We believe that our findings may be of interest. sKlotho
has been shown to exert diverse vasculoprotective functions,
as reviewed recently.12,13 We therefore consider sKlotho not
merely to represent a potential reflector of membrane Klotho
expression. Instead, any changes in sKlotho might directly
contribute to accelerated vascular disease in CKD patients.
Despite these theoretical considerations, sKlotho did not
predict event-free survival in our CKD cohort, whereas
elevated plasma FGF-23 was confirmed as an independent
predictor of adverse renal outcome even after adjustment for
potential confounders in multivariate regression analysis.
In summary, we present first data on plasma levels of
sKlotho and FGF-23 in a large cohort of CKD stage 2–4
patients, rebutting the hypothesis that CKD is characterized
by reduced plasma level of secreted Klotho. Moreover,
after a mean of 2.2±0.8 years of follow-up, FGF-23
outperformed sKlotho as a predictor of adverse outcome in
CKD patients.
MATERIALS AND METHODS
The ongoing CARE FOR HOMe study recruits CKD patients from
our nephrological outpatient clinic. The study was approved by the
local Ethics Committee, and all patients provided written informed
consent.
Patients were included if they had CKD stage 2–4 (defined as an
eGFR between 15 and 90ml/min per 1.73m2 according to MDRD
equation 4, based on KDOQI guidelines, subdividing CKD patients
with eGFR 30–59ml/min per 1.73m2 into stage 3a (eGFR 45–59ml/
min per 1.73m2) and stage 3b (eGFR 30–44ml/min per 1.73m2)).
Patients under systemic immunosuppressive medication and those
with concomitant human immunodeficiency virus infection, clinical
apparent infections (defined as CRP levels above 50mg/l, and/or
requiring systemic antibiotic therapy), active cancer disease,
malignant hematological disorders, and/or acute renal failure
(defined as increase of plasma creatinine 450% within four weeks)
were excluded from study participation. Moreover, we excluded
allograft recipients, pregnant women, and subjectso18 years of age.
A standardized questionnaire was used to record a history of
smoking, diabetes mellitus, current drug intake, and cardiovascular
comorbidity. In addition, comorbidity was assessed by chart review.
Prevalent cardiovascular disease was defined as a history of
myocardial infarction, coronary artery angioplasty/stenting/bypass
surgery, major stroke, carotid endarterectomy/stenting, nontrau-
matic lower extremity amputation, or lower limb artery bypass
surgery/angioplasty/stenting.
Patients were categorized as active smokers if they were current
smokers or had stopped smoking o1 month before entry into the
study. Patients with self-reported or physician-reported diabetes
mellitus, with a fasting blood glucose level of 4126mg/dl or with
current use of hypoglycemic medication, were categorized as
diabetic.
Body mass index was calculated as weight (kg)/(height (m))2.
Laboratory measurements
Blood samples were obtained under standardized conditions after an
overnight fasting. Within 15min, the samples were centrifuged at
4000 r.p.m. for 5min at room temperature. Supernatants were
immediately stored in aliquots at 80 1C until further use.
In those CARE FOR HOMe study participants who had been
recruited before 25 February 2011 (n¼ 321), we determined C-
terminal FGF-23 levels by ELISA (Immutopics, San Clemente, CA;
low cutoff value 1.5 rU/ml, high cutoff value 1500 rU/ml (samples
with FGF-2341500 rU/ml were measured after dilution)), as well as
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‘intact’ PTH (measured by second-generation ECLIA, Hoffmann-La
Roche, Baˆle, Switzerland; range of normal values 15–65 pg/ml),
calcium, and phosphate levels by standard laboratory methods. In
all 321 patients, human secreted a-Klotho levels were determined
by means of a sandwich ELISA (Immuno-Biological Labora-
tories, Fujioka-shi, Gunma, Japan).15 In brief, prediluted patient
sample (dilution one in two) was incubated at room temperature for
60min in a precoated microtiter plate (anti-human Klotho (67G3)
mouse IgG, affinity purified). After plate wash, a second 30-min
incubation with horseradish peroxidase–conjugated anti-human
Klotho (91F1) mouse IgG Fab (affinity purified) took place at
room temperature. After plate wash, the final reaction was visualized
by the addition of a chromogenic substrate and time-delayed
addition of a stop solution, followed by reading of absorbance at
450 nm.
To verify the capability of the a-Klotho Assay Kit to
quantitatively measure soluble a-Klotho, we performed linearity-
of-dilution experiments. Therefore, we purchased recombinant
human a-Klotho (rhKL; R&D Systems, Wiesbaden, Germany (Lot
Number SFN0811091)), and diluted rhKL to yield an initial
concentration of 1250 ng/l. We tested several different dilutions of
this sample in diluent solution (sample:diluent ratio 1:9, 2:8, 3:7,
4:6, 5:5, 6:4, 7:3, 8:2, and 9:1). We found a good recovery of rhKL
with a linear relationship between the sample:diluent ratio and
a-Klotho levels as measured by ELISA (compare Figure 4).
A spot urine sample was assessed to quantify urinary FePi and
calcium (FeCa) excretion according to the following formula:
FePi ¼ðurine phosphateplasma creatinineÞ=
ðplasma phosphateurine creatinineÞ100 and
FeCa ¼ðurine calciumplasma creatinineÞ=
ðplasma calciumurine creatinineÞ100:
All patients were invited annually for follow-up examinations.
The combined end point of our analysis was defined as the
occurrence of death, or as initiation of renal replacement therapy.
All patients were followed up until 31 December 2011.
Statistics
Data management and statistical analysis were performed with
PASW Statistics 18. The level of significance was set at Po0.05.
Categorical variables are presented as percentage of patients and
compared using the w2 test. Continuous data are expressed as
means±s.d., and were compared using one-way analysis of variance
test partitioning the between-groups sums of squares into trend
components. Albuminuria, Klotho, FGF-23, and CRP levels are
presented as median (interquartile range) because of skewed
distribution. The association between continuous variables was
assessed by Spearman’s rank correlation testing.
After stratifying subjects for plasma sKlotho, plasma FGF-23,
serum PTH, and FePi into tertiles, we assessed the prognostic impact
of each of these parameters on the combined end point by calculating
Kaplan–Meier survival curves, which were compared by log-rank test.
Finally, we calculated Cox regression models to analyze the
relationship between event-free survival and sKlotho, FGF-23,
PTH, or FePi after adjustment for potentially confounding variables.
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